Exxon Mobil stock is highly leveraged to the price of oil. So, if oil prices recover in 2019, XOM's share price should should spike higher. Read More

Rho is a gauge that helps you evaluate options contracts and their exposure to the risk of interest rate fluctuations. Here's how it works. Read More

We frequently advise investors to know their risk tolerance. Here's a time-tested measure for understanding the potential volatility in your portfolio. Read More

The rising incidence of hacking dominates the front pages. We examine cybersecurity firm Bravatek to see if it's a growth play or just another risky fad stock. Read More

Nike is one of the most recognizable brands in the world. The company has faced some stiff competition lately. Will it remain Number One? Read More

This global colossus dominates the thriving management consulting industry. But as the pace of change accelerates, can the company stay on top? Read More

There's a trio of economic trends that will drive the market higher this year. Shareholders of these three companies stand to benefit the most. Read More

An examination of Therapix Biosciences, its rivals, and a prediction for this micro-cap biotech stock in 2019. Will Therapix prove a winner or loser in the race to develop cannabis-based drugs? Read More

An examination of Supreme Cannabis stock, its rivals, whether it's overpriced or underpriced, and a prediction for the stock in 2019. Read More

Amazon's new headquarters near Washington DC could elevate Jeff Bezos’ legacy to something far greater than being remembered as the guy that wrecked retail. Read More

Our review of clinical-stage medical cannabis companies continues, with a fledgling biotech that's generating especially keen interest on Wall Street. Is Cara a future bonanza... or short-term fad? Read More

We examine a clinical-stage biotech making medicines from cannabis. Is the stock a hot prospect or is all the hype just a smokescreen for a fundamentally weak investment? Read More

We spotlight Intec Pharma, its rivals, and whether the stock is overpriced or underpriced. Is this Israel-based biotech on the verge of launching blockbuster new drugs? Read More

Marie Kondo's famous book on cleaning out your closet contains some helpful hints that are easily applied to your portfolio. Use this mid-winter bounce to clean out your stocks. Read More

An examination of this popular biotech stock, its rivals, whether it's overpriced or underpriced, and a prediction for its prospects in 2019. Read More

Zynerba Pharmaceuticals is a fledgling, small-cap maker of cannabis-based drugs. The stock has attracted considerable media interest, but is it too risky? We sift through the hype to examine the fundamentals. Read More